Impact and prevention of severe exacerbations of COPD: a review of the evidence
DMG Halpin, M Miravitlles, N Metzdorf… - International journal of …, 2017 - Taylor & Francis
Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …
implications for patients and significant economic consequences for society. The prevalence …
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
M Bafadhel, S Peterson, MA De Blas… - The Lancet …, 2018 - thelancet.com
Background The peripheral blood eosinophil count might help identify those patients with
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease …
S Pascoe, N Locantore, MT Dransfield… - The lancet Respiratory …, 2015 - thelancet.com
Background The short-term benefits of inhaled corticosteroids for patients with chronic
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …
FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease
DA Lipson, H Barnacle, R Birk, N Brealey… - American journal of …, 2017 - atsjournals.org
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
S Pascoe, N Barnes, G Brusselle… - The Lancet …, 2019 - thelancet.com
Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
KM Kew, A Seniukovich - Cochrane Database of Systematic …, 2014 - cochranelibrary.com
Background Inhaled corticosteroids (ICS) are anti‐inflammatory drugs that have proven
benefits for people with worsening symptoms of chronic obstructive pulmonary disease …
benefits for people with worsening symptoms of chronic obstructive pulmonary disease …
Inhaled corticosteroids in COPD and the risk of serious pneumonia
Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …
Prevention of acute exacerbations of COPD: American college of chest physicians and Canadian thoracic society guideline
GJ Criner, J Bourbeau, RL Diekemper, DR Ouellette… - Chest, 2015 - Elsevier
BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
M Miravitlles, A Auladell-Rispau… - European …, 2021 - Eur Respiratory Soc
Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD;
however, a significant proportion of patients at low risk of exacerbations are treated with …
however, a significant proportion of patients at low risk of exacerbations are treated with …
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group …
MT Dransfield, J Bourbeau, PW Jones… - The Lancet …, 2013 - thelancet.com
Background Whether the combination of a once-daily inhaled corticosteroid with a once-
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …